Points to Consider in the Development of Seed Stocks of Pluripotent Stem Cells for Clinical Applications: International Stem Cell Banking Initiative (ISCBI).
Peter W. Andrews,Duncan Baker,N Benvinisty,B Miranda,K. Bruce,Oliver Brüstle,Myeong Jun Choi,Yeona Choi,Jeremy M. Crook,Paul A. De Sousa,Petr Dvořák,Christian Freund,Meri T. Firpo,Miho Furue,Paul J. Gokhale,Hye‐Yeong Ha,Enna Han,Simone Haupt,Lyn Healy,Derek J. Hei,Outi Hovatta,Charles J. Hunt,S-M Hwang,Maneesha S. Inamdar,Rosario Isasi,Marisa Jaconi,Veronika Jekerle,P Kamthorn,Maura C. Kibbey,Ivana Knežević,Barbara B. Knowles,S-K Koo,Yacine Laâbi,L Leopoldo,P. Liu,Geoffrey Lomax,JF Loring,Tenneille E. Ludwig,Karen Dyer Montgomery,Christine L. Mummery,András Nagy,Yukio Nakamura,Norio Nakatsuji,Steve Oh,Timo Otonkoski,Martín F. Pera,Marc Peschanski,Patrícia Pranke,Kristiina Rajala,Rao Ms,Ruttachuk Rungsiwiwut,Benjamin Reubinoff,L. Ricco,Heather M. Rooke,Douglas Sipp,Glyn Stacey,Hirofumi Suemori,Tomoko Takahashi,Kei Takada,Sohel Talib,Shelly E. Tannenbaum,Bao‐Zhu Yuan,Fanyi Zeng,Qi Zhou
DOI: https://doi.org/10.2217/rme.14.93
2015-01-01
Regenerative Medicine
Abstract:In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications. The term ‘seed stock’ is used here to describe those cryopreserved stocks of cells established early in the passage history of a pluripotent stem cell line in the lab that derived the line or a stem cell bank, hereafter called the ‘repository’.